Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ. Lavoie JC, et al. Blood. 2005 Aug 15;106(4):1473-8. doi: 10.1182/blood-2004-12-4689. Epub 2005 May 3. Blood. 2005. PMID: 15870180 Free article.
The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Shenkier TN, Voss N, Chhanabhai M, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Morris J, O'Reilly SE, Pickles T, Sehn L, Connors JM. Shenkier TN, et al. Among authors: voss n. Cancer. 2005 Mar 1;103(5):1008-17. doi: 10.1002/cncr.20868. Cancer. 2005. PMID: 15651059 Free article.
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, et al. Reece DE, et al. Among authors: voss nj. Blood. 1995 Jul 15;86(2):451-6. Blood. 1995. PMID: 7541661 Free article. Clinical Trial.
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL. Reece DE, et al. Among authors: voss nj. Bone Marrow Transplant. 1999 Jun;23(11):1131-8. doi: 10.1038/sj.bmt.1701790. Bone Marrow Transplant. 1999. PMID: 10382952
99 results